Lilly's Pricing Pattern Eli Lilly has established a pattern with Zepbound that is likely to carry over to retatrutide: High list price ($1,000+/month), consistent with industry norms Competitive direct-to-consumer pricing through LillyDirect, undercutting retail pharmacy costs Savings programs for commercially insured patients Aggressive engagement with Medicare negotiations to secure broad coverage Lilly has been more transparent about consumer pricing than many pharmaceutical companies, and the success of LillyDirect for Zepbound suggests they will use a similar channel for retatrutide
Exercise Programs
Insurance coverage remains limited for all five options, though some HSA and FSA accounts accept peptide therapy expenses with proper documentation
Beneficiaries prescribed an eligible GLP-1 for a use coverable under standard Part D (e.g., Wegovy for CV risk reduction, Zepbound for OSA) do not qualify for that drug under the Bridge
After first use, keep it refrigerated or at room temperature below 30C and use within the recommended period
Additionally, the strongest environmental factors (duration of diabetes and HbA1c) only explained about 11% of the variation in DR risk in the DCCT trial and 10% in the WESDR study (12, 78)
